Characterization and comparative analysis of multifunctional natural killer cell engagers (NKCEs) during antitumor responses

T cell engagers (TCEs) are transformational oncology therapies but limited in use due to the induction of cytokine release syndrome (CRS). In comparison to T cells, natural killer (NK) cells produce less cytokines upon activation, leading to the exploration of NK cell engagers (NKCEs). However, why NK cells secrete less cytokines such as tumor necrosis factor (TNF) and how NKCEs perform directly against TCEs remain unclear. Here we report that relative to T cells, NK cells have reduced trafficking and processing of TNF. Systematic development and benchmarking studies show that NKCEs can be optimized to engage multiple activating receptors and incorporate the interleukin (IL)-2, thereby increasing their potency and durability. Furthermore, comparative studies of NKCE, IL-2, and TCE therapy in animal tumor models reveal both common and different therapeutic benefits. Our results provide a blueprint for development of multifunctional NKCEs that may serve as an alternative to current TCE therapies. CD4+ T, CD8+ T, and natural killer (NK) cells were treated either with PBS (control) or various T-cell engager (TCE) or NK-cell engager (NKCE) molecules, respectively. One molecule was tested on T-cells while several others were tested on NK cells. RNA pellets were collected both at 16H and 64H post-treatment.